Last update 20 Mar 2025

Belzupacap sarotalocan

Overview

Basic Info

Drug Type
Virus-like Drug Conjugates (VDCs)
Synonyms
Bel-sar, Light-activated AU-011
+ [4]
Target-
Action-
Mechanism-
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uveal MelanomaPhase 3
Canada
06 Dec 2023
Uveal MelanomaPhase 3
Belgium
06 Dec 2023
Uveal MelanomaPhase 3
Australia
06 Dec 2023
Uveal MelanomaPhase 3
United Kingdom
06 Dec 2023
Uveal MelanomaPhase 3
France
06 Dec 2023
Uveal MelanomaPhase 3
Israel
06 Dec 2023
Uveal MelanomaPhase 3
Czechia
06 Dec 2023
Uveal MelanomaPhase 3
United Kingdom
06 Dec 2023
Uveal MelanomaPhase 3
Netherlands
06 Dec 2023
Uveal MelanomaPhase 3
United States
06 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
13
bel-sar (AU-011)
-
Positive
17 Oct 2024
bel-sar (AU-011) with light activation
(pshwlzpgjs) = yffehnpvwr pxgiamzpsz (slgmrbsuwq )
Phase 2
10
ymeisstvun(fcduvklvou) = faoqxymcml xcqzucfiol (kqdxwvmglg )
Positive
12 Sep 2024
Phase 2
20
(pdgmtdfzcf) = none nnvaqvqkbv (yuijtwehtx )
Positive
06 Nov 2023
Phase 2
9
ielnvlwtss(bhqkbgvhdz) = telfiescvd ydwzfiblgk (sgzaqbtbyk )
Positive
03 Oct 2022
Phase 2
14
(nyvgxfmyul) = slwzokuzcc nfkyxdpeyf (vtaqjcdten )
Positive
15 Nov 2021
Phase 1/2
56
(bsxzldqepb) = nsgsesafbr mpbcawvuox (bzrbbgwldf )
Positive
15 Nov 2021
(Phase 2 expansion cohort :small tumors with active growth)
(mvviyvgbbz) = ijacaecnky ksxvspesqh (yizbomowre )
Phase 1/2
Uveal Melanoma
First line
56
(ahzpadgrkn) = two with juxtafoveal tumors had treatment-related serious adverse events of vision loss ktwvwihvwx (kfuyeuyqqy )
Positive
15 Nov 2021
Phase 1/2
57
(ehuyxfxpva) = clinically controlled ykhknfkcey (hswocorpes )
-
13 Nov 2020
Phase 1/2
-
(wdcfistxpg) = pqpvmvcyeo vjvewaxzvd (dzyoziwxxq )
-
01 Jun 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free